Quintiles Named a Preferred Provider to Global Health Product Development Partnership Consortium

RESEARCH TRIANGLE PARK, N.C. - Saturday, March 26th 2011 [ME NewsWire]

Quintiles announced today that it has been named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs) leveraging the combined size of their pipelines to ensure the most cost effective use of their research and development dollars.

PDPs are not-for-profit entities formed for the purpose of advancing global health and the health of the world’s poorest by the discovery, development and delivery of new effective and affordable medicines for the most neglected diseases in the world. The 14 PDPs anticipate funding 128 (phase I-IV) clinical trials over the next two years (2011-2013).

The consortium members are funded, in part, by the Bill and Melinda Gates Foundation which has committed $10 billion over the next 10 years to help research, develop and deliver vaccines and treatments for the world’s poorest countries, with a portion of that commitment directed to the PDPs. The PDPs also receive funding from government agencies, private entities and other sources.

Quintiles will partner with the consortium members by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly in the area of infectious diseases such as HIV, malaria and tuberculosis.

“Quintiles is extremely pleased to have been chosen by the consortium members,” said Dr. Kelly McKee, M.D., Quintiles Vice President and Managing Director, Public Health and Government Services. “The work they’re doing has the potential to reshape global health within a generation. The public health issues on which they are focused has the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Contacts

Quintiles

Phil Bridges, Media Relations, 919-998-1653 (o)

919-457-6347 (m)

phil.bridges@quintiles.com



Greg Connors, Investor Relations, 919-998-2000

invest@quintiles.com